CN Patent

CN106176662A — 4‑氨基‑2‑(2，6‑二氧代哌啶‑3‑基)异吲哚啉‑1，3‑二酮的制剂

Assigned to Celgene Corp · Expires 2016-12-07 · 9y expired

What this patent protects

本发明提供了4‑氨基‑2‑(2，6‑二氧代哌啶‑3‑基)异吲哚啉‑1，3‑二酮或其可药用立体异构体、前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。本发明还提供了治疗、控制或预防诸如癌症或炎症性疾病等各种疾病的方法。

USPTO Abstract

本发明提供了4‑氨基‑2‑(2，6‑二氧代哌啶‑3‑基)异吲哚啉‑1，3‑二酮或其可药用立体异构体、前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。本发明还提供了治疗、控制或预防诸如癌症或炎症性疾病等各种疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN106176662A
Jurisdiction
CN
Classification
—
Expires
2016-12-07
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.